Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Latest news & events

Latest news & events at the Wesfarmers Centre of Vaccines & Infectious Diseases.

Research

Trivalent influenza vaccine and febrile adverse events in australia, 2010: Clinical features and potential mechanisms

Increased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010.

Research

Sexual dimorphism in lung function responses to acute influenza A infection

Males are generally more susceptible to respiratory infections; however, there are few data on the physiological responses to such infections in males and...

Research

Safety surveillance of influenza vaccine in pregnant women

Vaccination is the most effective strategy for preventing influenza infection in pregnancy.

Research

Caregiver’s attitudes, beliefs, and experiences for influenza vaccination in Australian children with medical comorbidities

Influenza vaccination recommendation by children’s hospital physicians and previous vaccine receipt in hospital was associated with vaccine uptake

Research

Paediatrician beliefs and practices around influenza vaccination

We aimed to determine Australian paediatricians' beliefs and practices around the influenza vaccination of children.

Research

Geogenic PM10 exposure exacerbates responses to influenza infection

This study aimed to determine whether chronic, low-dose exposure to geogenic particulate matter <10μm diameter (PM10) exacerbates viral infections of the...

Research

Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation.

This study was designed to compare data collected via SMS and telephone for the purposes of monitoring vaccine safety.

Research

A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months

Respiratory syncytial virus (RSV) causes serious illness in children. The Ad26.RSV.preF vaccine candidate was immunogenic with acceptable safety in a phase 1/2a study of RSV-seropositive children. Here, we assessed its safety and immunogenicity in RSV-seronegative children.